INVESTIGATIONAL Preclinical‑stage. Not approved by FDA.
INVESTIGATIONAL Under development. Not cleared by FDA.

Investor Relations

Every disease
has a sequence.

Seek Labs is building the disease-response platform.

One genomic intelligence layer powers two product engines: Sequence Ablation Therapeutics and point-of-need molecular diagnostics, both engineered from the same conserved-sequence backbone. One intelligence architecture, two product categories, hundreds of diseases in scope.

Existing investors: log in to Pulley

Why Now

The last generation answered one disease at a time. The next generation is programmable.

  • 01

    Pathogen genomes are now read in hours, not years. AI can scan them at scale and pinpoint the conserved regions a virus cannot mutate without breaking itself — turning sequence into a target the same day it appears.

  • 02

    CRISPR has matured from a gene-editing tool into a programmable execution layer. The chassis stays the same; only the guide RNA changes. A new disease becomes a new program, not a new drug.

  • 03

    Computation closed the gap with chemistry. Modern sequence-design models read millions of pathogen and host genomes, predict which conserved regions are safe to hit, and rank candidate guides and probes before any wet-lab work begins — turning months of screening into hours at the keyboard.

  • 04

    SeekIt is being developed as an instrument-free, single-use molecular diagnostic for the point of need. Sealed cartridges. No thermocycler, no lab. As patient demand shifts toward at-home and near-patient testing, Seek Labs is building a platform designed to meet that need. SeekIt is investigational and not cleared by FDA.

The Opportunity

An unusual convergence. A company built for it.

Why now

Molecular medicine has reached an inflection point.

Every disease has a sequence, and that sequence contains vulnerabilities. AI now decodes entire disease families and pinpoints conserved regions in hours. CRISPR is programmable. What’s missing are the platforms that turn this convergence into detection and treatment at the speed of disease. That’s what Seek Labs is building.

Why us

One AI brain. Two platforms.

BioSeeker is AI-powered genomic discovery. It reads thousands of sequences to map the conserved regions a pathogen cannot mutate without losing essential function. From that map, it designs the molecular tools both platforms need: CRISPR guide RNAs for therapeutics, primer and probe sets for diagnostics. One brain. Two platforms.

Not a single-bet drug

When the next pathogen emerges, the platform is designed to respond without starting from zero.

25/25 WHO priority viral families mapped. 145+ infectious diseases mapped. When the next pathogen emerges, Seek Labs is not at day zero. In a preclinical swine challenge study, our CRISPR-based therapeutic candidate increased survival relative to untreated controls in African Swine Fever Virus. Additional studies are needed. Designed to be disease-agnostic, rapidly reprogrammable, and AI-guided. Designs against multiple priority pathogen families have already been generated.

Platform thesis

A platform
built on conserved biology.

A new category, not a new molecule. Sequence Ablation Therapeutics is a new modality. The same genomic logic that designs a therapeutic also designs a diagnostic, so every new program builds on the platform rather than starting from scratch.

A compounding platform. BioSeeker compounds in value. Every new pathogen mapped can expand the platform’s design reach without requiring a proportional expansion of the operating model. Because we design against conserved sequences a pathogen cannot mutate without losing fitness, the platform is designed to retain effectiveness as pathogens evolve.

Multiple paths forward, federal-anchored. Three programs advance in parallel from a single platform: licensable diagnostics with established field-validation partners, programmable therapeutics with USDA non-dilutive funding in hand, and biodefense engagement across BARDA RRPV, BioMaP, MCDC, MTEC, DARPA Connect, and NAVALX Vulcan. Three program tracks share one underlying platform.

BioSeeker™

AI genomic engine. 25/25 WHO priority viral families mapped.

SAT

Sequence Ablation Therapeutics. Programmable. Multi-site. Conserved-region targeting.

PTAP™

Programmable Target Ablation Platform. The therapeutic execution layer.

SeekIt™

Instrument-free, single-use diagnostic for the point of need. Investigational; not cleared by FDA.

ANINA™

Seek Amplification

Isothermal amplification chemistry. Field-ready, no thermocycler.

VELOX™

Seek Extraction

Sample preparation and extraction across tissue, blood, saliva, urine, swab.

Federal

Biodefense innovation pathways engaged.

BARDA RRPV · BioMaP · MCDC · MTEC · DARPA Connect · NAVALX Vulcan

Consortium membership does not imply endorsement of Seek Labs or its products by any U.S. government agency.

$2M

USDA grant awarded (2026)

Timeline · Bench to Platform

A decade of invention. A platform ready to deploy.

Seek Labs did not license its science out of a university or assemble it from acquired parts. The chemistry, the AI engine, and the platform chassis were all invented in-house. The years below trace that work — discovery, then translation, now deployment — with federal anchors and peer-reviewed results along the way.

2016

Founded in Salt Lake City

The company (formerly CibusDx) is founded to bring molecular diagnostics out of centralized labs.

2019

First Diagnostic Prototype

Early Seek Extraction cartridge validated with initial target panels.

2020

Rebrand to Seek Labs

Seek Labs expands beyond diagnostics into programmable therapeutics.

2023

BioSeeker Development Begins

Building begins on the genomic intelligence engine that now powers target discovery and design across Sequence Ablation Therapeutics and molecular diagnostics.

2023

ASFV Therapeutic Candidate Demonstrates 57% Survival

Seek Labs’ CRISPR-based therapeutic candidate achieved 57% survival in pigs challenged with African Swine Fever Virus, an early in vivo proof point for the company’s programmable therapeutic approach.

2024

Diagnostics External Validation Completed

Independent validation work was completed with ShrimpVet Laboratory in Vietnam and Florida Atlantic University, supporting third-party evaluation of Seek Labs’ field-deployable diagnostic kit.

2025

Programmable Therapeutics Research Published

Seek Labs’ peer-reviewed CRISPR therapeutic research was published in Viruses, advancing the scientific foundation behind its programmable infectious disease platform.

2025

25/25 WHO Priority Viral Families Mapped

BioSeeker maps every WHO priority viral family. The deepest comparative genomic atlas for programmable medicine.

2026

$2M USDA Grant Awarded

Seek Labs received federal funding to advance a programmable therapeutic targeting highly pathogenic avian influenza.

2026

First U.S. Patent Awarded

Seek Labs was awarded its first U.S. patent for isothermal molecular amplification chemistry designed to enable decentralized molecular testing.

2026

Federal and International Networks Expanded

Expanded presence across U.S. federal innovation networks, including BioMaP, BARDA RRPV, and MTEC, while advancing international collaborations.

—

More to come

Additional milestones will be added as Seek Labs advances its platforms, partnerships, and programs.

Partners & Networks

Inside the networks that matter.

Seek Labs is a member of the federal, defense, and global research consortia that drive medical countermeasure development, biomanufacturing readiness, and outbreak response — the access lanes we are building on.

  • BARDA RRPV Member of BARDA’s Rapid Response Partnership Vehicle, a dynamic network supporting accelerated countermeasure development.
  • BioMaP Member of the BARDA-aligned Biopharmaceutical Manufacturing Preparedness Consortium, advancing rapid, scalable manufacturing for medical countermeasures.
  • MCDC Member of the DoD’s Medical CBRN Defense Consortium, an alliance enhancing the mission effectiveness of military personnel.
  • MTEC Member of the DoD’s OTA, Medical Technology Enterprise Consortium, advancing the rapid deployment of innovative medical technologies.
  • DARPA Connect Member of DARPACONNECT, a gateway to defense opportunities and breakthrough technology development.
  • NAVALX Vulcan Member of NAVALX Vulcan under the Navy’s Rapid Capabilities Office to accelerate the delivery of innovative solutions to emerging challenges.
  • CURE Member of Cure, a premier healthcare innovation ecosystem helping innovators from concept to commercialization.
  • GARA Member of the Global African Swine Fever Research Alliance, a coordinated global research alliance enabling the progressive control and eradication of ASF.

Publications

The science behind the platform. Peer-reviewed and editorial publications from the Seek Labs team.

Governance

Board of Directors

Board includes members with scientific, operational, governance, and capital-markets experience.

Bill Stoddart

Bill Stoddart, MA

Board Chair, Co-Founder 45 North Partners

Randy Rasmussen

Randy Rasmussen, PhD

Co-Founder, BioFire Diagnostics

Cindy Dunkle

Cindy Dunkle

Biotech executive with leadership experience at Genentech and Denali Therapeutics.

Michael Paul

Michael Paul, PhD

CEO, Lineagen, MARAbio

Keith Marmer

Keith Marmer, MBA, DPT

Fmr. Chief Innovation Officer, University of Utah

Pete Koson

Pete Koson, MBA, CMA

Founder, Ninety South Consulting CFO Services

Current Investors

Access your portfolio, cap table, and documents through our Pulley portal.

If you are an existing Seek Labs investor, your equity details, documents, and cap table are available in Pulley. Log in below to access your account.

Log in to Pulley